Three Biotechs That Are Top Takeover Targets

"Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion. But here's what you should actually be watching."

"Shares trade near $988.87 after a 21.25% one-year run and a staggering 1,465.32% gain over ten years. The decade of compounding has happened. From here, the math gets harder. Novo Nordisk is the other half of the GLP-1 duopoly, and it is fighting a different battle."

"The interesting move is following where these giants are spending. Lilly's CEO David Ricks noted four acquisitions announced in Q1 2026 alone: Orna, Centessa, Kelonia, and Ajax. Novo's BD head conducted 200 meetings at the J.P. Morgan Healthcare Conference, fresh off the $4.7 billion Akero Therapeutics deal. Smart money tends to front-run acquirers rather than pay up at $880 billion."

"Viking Therapeutics (NASDAQ:VKTX) is the cleanest strategic fit. Lead asset VK2735 is a dual GLP-1/GIP agonist with both subcutaneous and oral formulations, and Phase 3 VANQUISH-1 was fully enrolled with more than 4,500 patients ahead of schedule. The oral Phase 2 delivered up to 12.2% body weight reduction in 13 weeks. With $706 million in cash and a market cap of just $3.69 billion, Viking is small enough to swallow and dangerous enough that Novo cannot afford to let Lilly grab it."

Mounjaro revenue rose 125% to $8.66 billion last quarter, and full-year revenue guidance increased to $82 to $85 billion. The stock trades near $988.87 after a 21.25% one-year gain and a 1,465.32% ten-year gain, leaving less room for easy returns. Novo Nordisk faces weaker results, with Q4 2025 revenue down 7.6% year over year and US operations down 15%, alongside guidance for 2026 sales and operating profit to decline 5% to 13% at constant exchange rates. Competitive pressure is linked to pricing headwinds. Attention shifts to where companies allocate capital, including multiple Lilly acquisitions and Novo’s recent deal activity. Viking Therapeutics is highlighted as a strategic acquisition candidate due to its dual GLP-1/GIP asset, advanced trial progress, and small market capitalization.

Read at 24/7 Wall St.